JP2019530739A5 - - Google Patents

Download PDF

Info

Publication number
JP2019530739A5
JP2019530739A5 JP2019532215A JP2019532215A JP2019530739A5 JP 2019530739 A5 JP2019530739 A5 JP 2019530739A5 JP 2019532215 A JP2019532215 A JP 2019532215A JP 2019532215 A JP2019532215 A JP 2019532215A JP 2019530739 A5 JP2019530739 A5 JP 2019530739A5
Authority
JP
Japan
Prior art keywords
pyridin
trifluoromethyl
sulfonamide
chloro
sulfamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019532215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530739A (ja
JP7035055B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/055162 external-priority patent/WO2018042316A1/en
Publication of JP2019530739A publication Critical patent/JP2019530739A/ja
Publication of JP2019530739A5 publication Critical patent/JP2019530739A5/ja
Application granted granted Critical
Publication of JP7035055B2 publication Critical patent/JP7035055B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019532215A 2016-08-29 2017-08-28 N-(ピリジン-2-イル)ピリジン-スルホンアミド誘導体および疾患の処置におけるそれらの使用 Expired - Fee Related JP7035055B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380659P 2016-08-29 2016-08-29
US62/380,659 2016-08-29
PCT/IB2017/055162 WO2018042316A1 (en) 2016-08-29 2017-08-28 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease

Publications (3)

Publication Number Publication Date
JP2019530739A JP2019530739A (ja) 2019-10-24
JP2019530739A5 true JP2019530739A5 (OSRAM) 2020-08-27
JP7035055B2 JP7035055B2 (ja) 2022-03-14

Family

ID=59923496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019532215A Expired - Fee Related JP7035055B2 (ja) 2016-08-29 2017-08-28 N-(ピリジン-2-イル)ピリジン-スルホンアミド誘導体および疾患の処置におけるそれらの使用

Country Status (15)

Country Link
US (2) US10450273B2 (OSRAM)
EP (1) EP3504194B1 (OSRAM)
JP (1) JP7035055B2 (OSRAM)
KR (1) KR20190040319A (OSRAM)
CN (1) CN109641873B (OSRAM)
AR (1) AR109437A1 (OSRAM)
AU (1) AU2017319430A1 (OSRAM)
BR (1) BR112019003883A2 (OSRAM)
CA (1) CA3031073A1 (OSRAM)
EA (1) EA201990609A1 (OSRAM)
ES (1) ES2898069T3 (OSRAM)
MX (1) MX2019002439A (OSRAM)
TW (1) TW201811766A (OSRAM)
UY (1) UY37379A (OSRAM)
WO (1) WO2018042316A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201811766A (zh) * 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
KR102825974B1 (ko) 2016-09-13 2025-06-30 삼성디스플레이 주식회사 표시 장치
CN112638898B (zh) * 2018-08-31 2024-04-09 泽农医药公司 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途
JP2022514253A (ja) * 2018-12-18 2022-02-10 ノバルティス アーゲー N-(ピリジン-2-イルスルホニル)シクロプロパンカルボキサミド誘導体及びcftr媒介疾患の処置におけるその使用
MX2021007592A (es) * 2018-12-21 2021-08-11 Novartis Ag Compuestos macrociclicos y su uso en el tratamiento de enfermedades.
CN113423702A (zh) * 2019-02-06 2021-09-21 诺华股份有限公司 N-(吡啶-2-基)吡啶-磺酰胺衍生物及其在治疗疾病中的用途
AR118555A1 (es) 2019-04-03 2021-10-20 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CA3150162A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
TWI867024B (zh) * 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
SI4013741T1 (sl) 2019-08-14 2024-06-28 Vertex Pharmaceuticals Incorporated Postopek za izdelavo cftr-modulatorjev
MX2022005810A (es) * 2019-11-12 2022-06-08 Genzyme Corp Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de regulador de la conductancia transmembrana de la fibrosis quistica (cftr) deficiente.
IL292966A (en) * 2019-11-12 2022-07-01 Genzyme Corp Heteroarylaminosulfonamides with 5 positions and methods of using them
CN114867702A (zh) * 2019-12-13 2022-08-05 罗地亚经营管理公司 苯衍生物的生产
US20230277550A1 (en) 2020-08-20 2023-09-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for Treating Respiratory Diseases Characterized by Mucus Hypersecretion
EP4259139A1 (en) 2020-12-10 2023-10-18 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3642795A (en) 1994-09-27 1996-04-19 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
US5939431A (en) * 1996-06-20 1999-08-17 Schering Corporation Naphthyridines which affect IL-4 and G-CSF
JP2002514195A (ja) 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジン化合物およびそれの使用
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
AU2003226927A1 (en) 2002-04-09 2003-10-27 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
EP2172460A1 (en) 2002-11-01 2010-04-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20040204422A1 (en) 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
SE0301654D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US20070099938A1 (en) 2003-10-24 2007-05-03 Ono Pharmaceutical Co., Ltd. Antistress drug and medical use thereof
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
US7820704B2 (en) 2004-04-20 2010-10-26 Transtech Pharma, Inc. Substituted heteroaryl derivatives, compositions, and methods of use
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
EP1786782B1 (en) 2004-08-12 2010-03-31 Amgen Inc. Bisaryl-sulfonamides
BRPI0516454A (pt) 2004-10-04 2008-09-02 Hoffmann La Roche compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, sua utilização, método para o tratamento e profilaxia de enfermidades, e de diabetes do tipo ii
EP1666467A1 (en) 2004-11-08 2006-06-07 Evotec AG 11Beta-HSD1 Inhibitors
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
WO2007021941A2 (en) 2005-08-16 2007-02-22 Icagen, Inc. Inhibitors of voltage-gated sodium channels
BRPI0615094A2 (pt) 2005-08-25 2011-05-03 Hoffmann La Roche inibidores de p38 map cinase e métodos de uso dos mesmos
FR2896798A1 (fr) 2006-01-27 2007-08-03 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
EP2016075A1 (en) 2006-05-03 2009-01-21 AstraZeneca AB Thiazole derivatives and their use as anti-tumour agents
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
AU2007272972B2 (en) 2006-07-14 2011-12-01 Chemocentryx, Inc. Triazolyl pyridyl benzenesulfonamides as CCR2 or CCR9 modulators for the treatment of atherosclerosis
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
EP2054056A4 (en) 2006-08-16 2010-08-25 J David Gladstone Inst A Testa SMALL MOLECULAR INHIBITORS OF KYNURENINE-3-MONOOXYGENASE
AU2007293653B2 (en) 2006-09-08 2011-02-17 Novartis Ag N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions
WO2008033455A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
ES2732230T3 (es) 2007-04-11 2019-12-12 Canbas Co Ltd Compuestos que anulan el punto de control G2 del ciclo celular para una utilización en el tratamiento del cáncer
WO2008157500A1 (en) 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
WO2009055418A1 (en) 2007-10-22 2009-04-30 Smithkline Beecham Corporation Pyridosulfonamide derivatives as pi3 kinase inhibitors
WO2009098576A1 (en) 2008-02-05 2009-08-13 Pfizer Inc. Pyridinyl amides for the treatment of cns and metabolic disorders
EA201001847A1 (ru) 2008-06-11 2011-08-30 Айрм Ллк Соединения и композиции, применяемые для лечения малярии
WO2010029300A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Bis aromatic compounds for use in the treatment of inflammation
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
WO2010123822A1 (en) 2009-04-20 2010-10-28 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine sulfonamide derivatives
EP2253617A1 (de) 2009-05-20 2010-11-24 Bayer CropScience AG Halogen-substituierte Verbindungen als Pestizide
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
CA2803695A1 (en) 2010-06-28 2012-01-05 Bayer Intellectual Property Gmbh Heteroaryl-substituted pyridine compounds for use as pesticides
WO2012004293A2 (de) 2010-07-08 2012-01-12 Bayer Cropscience Ag Insektizide und fungizide wirkstoffkombinationen
KR20130119964A (ko) 2010-12-22 2013-11-01 퍼듀 퍼머 엘피 나트륨 채널 차단제로서의 치환된 피리딘
US9295676B2 (en) 2011-03-17 2016-03-29 The Trustees Of The University Of Pennsylvania Mutation mimicking compounds that bind to the kinase domain of EGFR
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013134562A1 (en) * 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
CA2881357C (en) 2012-08-21 2020-12-08 Peter Maccallum Cancer Institute Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof
EP2888256A4 (en) 2012-08-24 2016-02-17 Univ Texas HETEROCYCLIC HIF ACTIVITY MODULATORS FOR THE TREATMENT OF DISEASES
US20140371238A1 (en) 2013-03-13 2014-12-18 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
JP2017503772A (ja) 2013-12-23 2017-02-02 ノージン ビーブイ Ccr9阻害剤としてのベンゼンスルホンアミド
WO2015138934A1 (en) * 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
PT3203840T (pt) 2014-10-06 2020-10-27 Vertex Pharma Moduladores do regulador da condutância transmembranar da fibrose quística
CN104844566B (zh) 2014-12-12 2018-05-18 合肥中科普瑞昇生物医药科技有限公司 一种新型结构的激酶抑制剂
BR112017026132A2 (pt) 2015-06-02 2018-08-28 AbbVie S.à.r.l. piridinas substituídas e métodos de uso
US9981945B2 (en) 2015-10-07 2018-05-29 NuBridge BioSciences Pyrimidine derivatives as CFTR modulators
GB201602527D0 (en) * 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
US10738030B2 (en) 2016-03-31 2020-08-11 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
TW201811766A (zh) * 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途

Similar Documents

Publication Publication Date Title
JP2019530739A5 (OSRAM)
US11129832B2 (en) Biheteroaryl compounds and uses thereof
RU2484091C2 (ru) Производные изоксазоло-пиридина
AU2018204431B2 (en) Compounds useful as inhibitors of ATR kinase
US8957074B2 (en) Pyrrolopyrimidine compounds as inhibitors of CDK4/6
CA2900855C (en) Aminopyrimidinyl compounds
JP2017524007A5 (OSRAM)
HRP20210177T1 (hr) Supstituirani spojevi pirazolo[1,5-a]piridina kao inhibitori ret kinaze
ES2637588T3 (es) Nuevos compuestos tricíclicos
US20230233692A1 (en) Compounds for targeted degradation of ret
JP2021506858A5 (OSRAM)
JP2019535664A5 (OSRAM)
JP2016535003A5 (OSRAM)
JP2017505327A5 (OSRAM)
JP2018500376A5 (OSRAM)
JP2013515070A5 (OSRAM)
GB2609879A (en) Antagonists of the adenosine A2a receptor
EP2548877A1 (en) 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
JP2025535046A (ja) Kras g12c変異タンパク質の複素環阻害剤及びその使用
JPWO2021076602A5 (OSRAM)
HRP20210285T1 (hr) Derivati ((piridin-2-il)-amino)pirido[3,4-d]pirimidina i ((piridazin-3-il)-amino)pirido[3,4-d]pirimidina kao inhibitori cdk4/6 za liječenje npr. reumatoidnog artritisa, arterioskleroze, plućne fibroze, cerebralnog infarkta ili raka
JP2015512427A5 (OSRAM)
JPWO2022208269A5 (OSRAM)
US20240360134A1 (en) Pyrazolopyrimidines and their uses as pdgfr inhibitors
WO2025194057A1 (en) Macrocyclic compounds as modulators of kras and uses thereof